Directors Gaby L. Longsworth, Ph.D. and Robert Greene Sterne will present a webinar titled "Patenting Compounds, Compositions, and Methods for Viral Infections: Patent Eligibility Considerations and Challenges" on Wednesday, October 7, 2020 from 1:00 p.m. to 2:30 p.m. EDT. This webinar is hosted by Strafford.
The COVID-19 pandemic has turned a spotlight on the issues surrounding patenting antiviral research and protecting IP rights for companies developing treatments and products to diagnose and battle viral infections. Understanding the viral mechanisms of action is critical to IP protection.
Beyond these mechanisms, patent counsel must then consider whether the antiviral and vaccine will be patent eligible. Like other patent claims, compound, composition, and method claims for viral infections must have novel, non-obvious, and useful properties. While novel compounds may often be easier to patent, vaccines include multiple layers of patents from formulations to manufacturing to methods of use.
Patent counsel and applicants must navigate the patent eligibility challenges as companies race to develop vaccines and medications to treat viral infections.
Listen as our authoritative panel of patent attorneys examines patenting issues for compounds, compositions, and methods for viral infections. The panel will discuss subject matter eligibility and recent court treatment. The panel will also offer best practices for addressing patent eligibility issues.
- Viral mechanisms
- Subject matter eligibility for compound, composition, and method patents
- Court treatment
- Best practices
The panel will review these and other key issues:
- What are the critical patentability issues when preparing compound or composition patents?
- How have the courts treated medical diagnostics claims?
- What strategies should counsel employ to increase the likelihood of getting patent protection for compounds, composition, or methods claims for viral infections?